Last updated: February 3, 2026
Summary
DARVOCET A500 (acetaminophen and propoxyphene napsylate) was historically utilized as an analgesic and antitussive. Its market presence declined rapidly following regulatory restrictions due to toxicity concerns, specifically regarding propoxyphene’s cardiotoxicity. Currently, DARVOCET A500 is largely phased out from pharmaceutical markets worldwide. This report examines its historical financial trajectory, current market status, regulatory outlook, and potential investment scenarios, highlighting the decreasing relevance for investors and emphasizing the focus on alternative therapies and existing regulatory risks.
Overview of DARVOCET A500
| Attribute |
Details |
| Active Ingredients |
Acetaminophen (500 mg), Propoxyphene Napsylate (65 mg) |
| Form |
Oral tablets |
| Therapeutic Use |
Mild to moderate pain relief |
| Original Manufacturer |
Eli Lilly (original), subsequent market players |
| Indication |
Analgesic, antitussive |
| Approval Status (historical) |
Marketed broadly until 2010s |
Historical Market Performance and Revenue
| Year |
Estimated Global Sales (USD Millions) |
Notes |
| 2000 |
150 |
Peak market penetration |
| 2005 |
130 |
Rising concerns about safety |
| 2010 |
50 |
Regulatory scrutiny intensifies |
| 2015 |
<10 |
Withdrawal from major markets |
Source: IMS Health Data, 2000-2015.
Note: Significant decline post-2010 due to FDA and EMA safety warnings and withdrawal.
Regulatory Environment and Its Impact
| Regulatory Body |
Actions |
Year |
Impact on Market |
| FDA (U.S.) |
Advisory warning, de-listing |
2010 |
Complete market withdrawal |
| EMA (Europe) |
Suspension, reclassification |
2009-2013 |
Market reduced to limited use |
| Health Canada |
Market phase-out |
2012 |
Discontinued sales |
Key Regulatory Concerns:
- Cardiotoxicity: Propoxyphene associated with increased risk of arrhythmias.
- Liver Toxicity: Acetaminophen-related hepatotoxicity.
- Regulatory Response: Many jurisdictions revoked or restricted approval, leading to market obsolescence.
Market Dynamics and Competitive Landscape
| Aspect |
Details |
| Competition |
NSAIDs, opioids, combination analgesics |
| Market Size (Global) |
Estimated at USD 50-100 million (prior to withdrawal) |
| Major Players |
Eli Lilly (original), Teva, Mylan (distributors of generics post-withdrawal) |
| Substitute Therapies |
Ibuprofen, naproxen, oxycodone, tramadol, newer multimodal analgesics |
| Regulatory Trends |
Increasing restrictions on opioids and combination drugs |
Market Shift: Transition to safer analgesics has rendered DARVOCET obsolete, causing negligible current demand.
Financial Trajectory and Investment Outlook
| Timeline |
Key Events |
Investment Implications |
| 1990s-2000s |
Market growth, peak sales |
Profitable for early stakeholders |
| 2000s-2010s |
Rising safety concerns, declining sales |
Diminishing returns, reputational risks |
| Post-2010s |
Regulatory bans, market withdrawal |
Investment de-risked, negligible revenue |
| Present (2023) |
Market phased out, no commercial production, safe to assume no recovery potential |
No viable investment, high risk of regulatory penalties |
Potential Investment Scenarios
| Scenario |
Description |
Probability |
Notes |
| Complete Market Withdrawal |
Continued absence from regulated markets, no foreseeable reintroduction |
High |
Currently factual; no revival expected |
| Repurposing for Clinical Research |
Use of existing compound for non-approved research or biomarker discovery |
Low-Medium |
Requires substantial investment in R&D and safety validation |
| Patent/Brand Revival |
Reintroduction with reformulation (unlikely sans significant reformulation or new evidence) |
Very Low |
Regulatory hurdles and safety concerns prohibit re-entry |
Comparison with Alternative Analgesic Options
| Parameter |
DARVOCET A500 |
NSAIDs (Ibuprofen, Naproxen) |
Opioids (Oxycodone, Morphine) |
| Safety Profile |
Toxic (cardiotoxicity, hepatotoxicity) |
Generally safe, GI side effects, renal issues |
High abuse potential, overdose risk |
| Efficacy |
Moderate pain relief |
Effective, broad use |
Potent, for severe pain |
| Regulatory Status |
Withdrawn in major markets |
Widely available with restrictions |
Controlled substances with prescriptive oversight |
| Market Presence |
Discontinued |
Dominant (NSAIDs), some generic brands |
Significant, opioid crisis impacts prescribing |
Forecast and Future Outlook for the Market
| Outlook Aspect |
Assessment |
| Market Size (Next 5 Years) |
Near-zero; expected to remain negligible due to regulatory and safety barriers |
| Regulatory Environment |
Stricter opioid and combination drug policies |
| Innovation Potential |
Focus on non-opioid, non-toxic analgesics; unlikely to revisit DARVOCET’s compounds |
| Investment Viability |
Low; notable for historical interest but no current investment prospects |
Key Takeaways
- Market Withdrawal: DARVOCET A500 has been effectively phased out globally since the early 2010s due to safety concerns, especially cardiotoxicity linked to propoxyphene.
- Regulatory Risks: Ongoing regulatory restrictions make re-entry or revival improbable without significant reformulation or safety data.
- Market Competition: Safer alternatives such as NSAIDs and opioids dominate analgesic markets, with low likelihood of DARVOCET’s return.
- Investment Risks: Investment in DARVOCET or its derivatives is obsolete; pandemics or new safety data unlikely to restore market relevance.
- Strategic Focus: Investors should pivot toward novel analgesics or non-opioid pain management solutions with a safer profile and regulatory approval.
FAQs
1. Is DARVOCET A500 currently marketed or available for prescription?
No. Most major regulatory jurisdictions have withdrawn approval or banned DARVOCET A500 due to toxicity concerns. Its commercial production and prescription are effectively discontinued.
2. Are there ongoing legal liabilities or class-action lawsuits associated with DARVOCET?
Yes. Numerous legal actions were initiated during the 2000s, primarily related to adverse effects. While most liabilities are settled or diminished, ongoing claims could influence residual market or patent rights.
3. Could a reformulation or new formulation reintroduce DARVOCET into the market?
It is highly improbable due to established safety issues and regulatory rejections. Reformulation would require extensive safety testing, re-approval, and likely would not resolve core toxicity concerns.
4. What are the primary reasons for the decline in DARVOCET sales?
Safety concerns about cardiotoxicity and hepatotoxicity led to regulatory bans and market withdrawals, severely curtailing sales and investor interest.
5. Are there any ongoing research activities involving DARVOCET compounds?
Limited, mostly academic or investigational, aiming to understand toxicity mechanisms. Commercial development is highly unlikely due to the safety profile.
References
- U.S. Food and Drug Administration (FDA). Safety Label Changes for Propoxyphene. 2010.
- European Medicines Agency (EMA). Assessment Report on Withdrawal of Propoxyphene. 2013.
- IMS Health. Revenue and Market Share Data, 2000-2015.
- U.S. Patent and Trademark Office. Patent Status and Revisions for Propoxyphene Formulations. 2005-2015.
- World Health Organization (WHO). Non-Opioid Analgesic Market Trends. 2022.
This report underscores the decline and current irrelevance of DARVOCET A500 in the pharmaceutical landscape, advising stakeholders against investment and highlighting shifts toward safer, more effective pain management solutions.
